OncoResponse, Inc.
- Biotech or pharma, therapeutic R&D
OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s anti-LILRB2 monoclonal antibody, OR502, is in efficacy confirming clinical studies in cutaneous melanoma and NSCLC, having achieved PRs and showed a 65% disease control rate in Phase 1 dose escalation studies, is being substantially funded by a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). OncoResponse is aligned with CPRIT, Oxford Finance, MD Anderson Cancer Center, Rivervest, ARCH Ventures, 3B Future, Canaan, Intervest, Takeda Ventures and Bering Capital. For more information please visit www.oncoresponse.com and follow us on LinkedIn and Twitter.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}